03 enero 2021

Pharmamar . Posiciones a 31-12-20 Según MorningStar

PharmaMar. La Biofarmacéutica también había ido demasiado lejos en su tendencia alcista, según Turazzini (  Consejera Delegada de Blackbird Bank ) . 

De hecho se deprecia más del 45% desde su récord del 20 de julio. 

 Darío García ( Analista de XTB )  Reconoce que han sacado al valor de cartera, al ser de las compañías más volátiles del Ibex por los cambios en sus investigaciones.








Para Morín ( Analista de IG Markets ) , Pharma Mar "podría ser un acierto para aquellos inversores deseosos de riesgos y especulativos", dada la intensa fluctuación de su cotización.

Las acciones presentan un potencial alcista de más del 42%, según el consenso de las seis firmas que siguen el valor. La mitad se inclina por mantener. ...


FDA Grants Orphan Drug Designation To Annamycin For Soft Tissue Sarcoma .

 

The FDA granted orphan drug designation to annamycin for the treatment of patients with soft tissue sarcoma, according to a manufacturer-issued press release.

Annamycin (Moleculin Biotech) is a next-generation liposome-formulated anthracycline designed to eliminate cardiotoxicity and avoid multidrug resistance mechanisms associated with other approved anthracyclines. ...

Australia . $10 Million For High Potential COVID-19 Related Clinical Trials .


Project

Recipient

Funding

Prevention of SARS-CoV-2 transmission in aged care (PreSTAC): Effective evidence-based measures for rapid translation using ultraviolet light

Prof Geraint Rogers, South Australian Health and Medical Research Institute Limited

$1,366,094

Accelerated phase I trial of targeted and tunable SARS-Cov-2 spike protein receptor binding domain recombinant protein and mRNA vaccines

Prof Terry Nolan, University of Melbourne

$1,588,283

3D-Printed Facial Guards to reduce P2/N95 respirator leak and protect health care workers from COVID-19

Assoc Prof Anand Ganesan, Flinders University

$973,119

Statin Treatment for COVID-19 to optimise Neurological Recovery (STRONGER) trial – using Statins to prevent brain complications as a result of COVID-19

Prof Craig Anderson, University of New South Wales

$2,375,779

Use of Cardioprotective Therapy to Manage Persistent Cardiovascular Effects of COVID-19: A Pathway to Recognition and Treatment of Subclinical Disease

Prof Thomas Marwick, University of Melbourne

$2,574,943

The Pomerium Trial: Protecting Aged Care Residents from the Pandemic via Specialised Nutritional Supplementation.

Prof Gustavo Duque, University of Melbourne

$1,189,527

Total

 

$10,067,745